Vitexin-4''-O-glucoside NEW
Price | $90 |
Package | 20mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-13 |
Product Details
Product Name: Vitexin-4''-O-glucoside | CAS No.: 178468-00-3 |
Purity: 99.64% | Supply Ability: 10g |
Release date: 2024/11/13 |
Product Introduction
Bioactivity
名稱 | Vitexin-4''-O-glucoside |
描述 | Vitexin-4''-O-glucoside (Vitexin -4''-O-glucoside) could effectively protect ECV-304 cells against cytotoxicity induced by TBHP through resuming mitochondrial function. |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 11 mg/mL (18.5 mM) |
關(guān)鍵字 | Vitexin4''Oglucoside | Vitexin 4'' O glucoside | inhibit | Inhibitor | Vitexin-4''-O-glucoside |
相關(guān)庫 | 黃酮類天然產(chǎn)物庫 | 中藥單體化合物庫 | 經(jīng)典已知活性庫 | 植物來源化合物庫 | 糖類及苷類化合物庫 | 天然產(chǎn)物庫 | NO PAINS 化合物庫 | 高通量篩選天然產(chǎn)物庫 | 已知活性化合物庫 | 藥食同源庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$40.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-09-21 | |
$908.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
$0.00/25MG |
VIP3Y
|
Changsha Staherb Natural Ingredients Co., Ltd.
|
2022-09-05 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY